Modeling of Tumor Progression in NSCLC and Intrinsic Resistance to TKI in Loss of PTEN Expression

PLoS ONE

Volumn 7, Issue 10, 2012, Pages

  Bidkhori, Gholamreza ^a   Moeini, Ali ^a   Masoudi Nejad, Ali ^a  

^a UNIVERSITY OF TEHRAN   (Iran)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; RAS PROTEIN; STAT3 PROTEIN;

ARTICLE; CANCER RESISTANCE; CELL PROLIFERATION; CELL SURVIVAL; ENZYME ACTIVITY; ENZYME INHIBITION; LUNG CARCINOGENESIS; LUNG NON SMALL CELL CANCER; MATHEMATICAL MODEL; MUTATIONAL ANALYSIS; PROTEIN EXPRESSION; PROTEIN SYNTHESIS INHIBITION; SIGNAL TRANSDUCTION;

CARCINOMA, NON-SMALL-CELL LUNG; COMPUTER SIMULATION; DRUG RESISTANCE, NEOPLASM; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LUNG NEOPLASMS; MODELS, BIOLOGICAL; MODELS, STATISTICAL; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEINS C-AKT; PTEN PHOSPHOHYDROLASE; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR;

EID: 84868089503     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0048004     Document Type: Article

References (113)

1. Hynes NE, Lane HA, (2005) ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer 5: 341-354.
2. Carpenter G, (1983) The biochemistry and physiology of the receptor-kinase for epidermal growth factor. Mol Cell Endocrinol 31: 1-19.
3. Carpenter G, Cohen S, (1990) Epidermal growth factor. J Biol Chem 265: 7709-7712.
4. Wells A, (1999) EGF receptor. Int J Biochem Cell Biol 31: 637-643.
5. Wiley HS, Shvartsman SY, Lauffenburger DA, (2003) Computational modeling of the EGF-receptor system: a paradigm for systems biology. Trends Cell Biol 13: 43-50.
6. Ciardiello F, Tortora G, (2001) A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor. Clin Cancer Res 7: 2958-2970.
7. Piyathilake CJ, Frost AR, Manne U, Weiss H, Bell WC, et al. (2002) Differential expression of growth factors in squamous cell carcinoma and precancerous lesions of the lung. Clin Cancer Res 8: 734-744.
8. Parkin DM, (2001) Global cancer statistics in the year 2000. Lancet Oncol 2: 533-543.
9. Jemal A, Siegel R, Xu J, Ward E, (2010) Cancer statistics, 2010. CA Cancer J Clin 60: 277-300.
10. Brambilla E, Travis WD, Colby TV, Corrin B, Shimosato Y, (2001) The new World Health Organization classification of lung tumours. Eur Respir J 18: 1059-1068.
11. Pore MM, Hiltermann TJ, Kruyt FA (2010) Targeting apoptosis pathways in lung cancer. Cancer Lett.
12. Fujino S, Enokibori T, Tezuka N, Asada Y, Inoue S, et al. (1996) A comparison of epidermal growth factor receptor levels and other prognostic parameters in non-small cell lung cancer. Eur J Cancer 32A: 2070-2074.
13. Dittadi R, Gion M, Pagan V, Brazzale A, Del Maschio O, et al. (1991) Epidermal growth factor receptor in lung malignancies. Comparison between cancer and normal tissue. Br J Cancer 64: 741-744.
14. Nicholson RI, Gee JM, Harper ME, (2001) EGFR and cancer prognosis. Eur J Cancer 37Suppl 4: S9-15.
15. Krause DS, Van Etten RA, (2005) Tyrosine kinases as targets for cancer therapy. N Engl J Med 353: 172-187.
16. Hirsch FR, Varella-Garcia M, Bunn PA Jr, Di Maria MV, Veve R, et al. (2003) Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis. J Clin Oncol 21: 3798-3807.
17. Amann J, Kalyankrishna S, Massion PP, Ohm JE, Girard L, et al. (2005) Aberrant epidermal growth factor receptor signaling and enhanced sensitivity to EGFR inhibitors in lung cancer. Cancer Res. 2005/01/25 ed. 226-235.
18. Kosaka T, Yatabe Y, Endoh H, Kuwano H, Takahashi T, et al. (2004) Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications. Cancer Res 64: 8919-8923.
19. Gow CH, Shih JY, Chang YL, Yu CJ, (2005) Acquired gefitinib-resistant mutation of EGFR in a chemonaive lung adenocarcinoma harboring gefitinib-sensitive mutation L858R. PLoS Med 2: e269.
20. Inukai M, Toyooka S, Ito S, Asano H, Ichihara S, et al. (2006) Presence of epidermal growth factor receptor gene T790M mutation as a minor clone in non-small cell lung cancer. Cancer Res 66: 7854-7858.
21. Kobayashi S, Boggon TJ, Dayaram T, Janne PA, Kocher O, et al. (2005) EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 352: 786-792.
22. Yasuda H, Kobayashi S, Costa DB (2011) EGFR exon 20 insertion mutations in non-small-cell lung cancer: preclinical data and clinical implications. Lancet Oncol.
23. Zhu JQ, Zhong WZ, Zhang GC, Li R, Zhang XC, et al. (2008) Better survival with EGFR exon 19 than exon 21 mutations in gefitinib-treated non-small cell lung cancer patients is due to differential inhibition of downstream signals. Cancer Lett 265: 307-317.
24. Sordella R, Bell DW, Haber DA, Settleman J, (2004) Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science 305: 1163-1167.
25. Greulich H, Chen TH, Feng W, Janne PA, Alvarez JV, et al. (2005) Oncogenic transformation by inhibitor-sensitive and-resistant EGFR mutants. PLoS Med 2: e313.
26. Nagatomo I, Kumagai T, Yamadori T, Furukawa M, Takahashi R, et al. (2006) The gefitinib-sensitizing mutant epidermal growth factor receptor enables transformation of a mouse fibroblast cell line. DNA Cell Biol 25: 246-251.
27. Sharma SV, Bell DW, Settleman J, Haber DA, (2007) Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer 7: 169-181.
28. Wakeling AE, Guy SP, Woodburn JR, Ashton SE, Curry BJ, et al. (2002) ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy. Cancer Res 62: 5749-5754.
29. Wakeling AE, (2005) Inhibitors of growth factor signalling. Endocr Relat Cancer 12Suppl 1: S183-187.
30. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, et al. (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350: 2129-2139.
31. Mulloy R, Ferrand A, Kim Y, Sordella R, Bell DW, et al. (2007) Epidermal growth factor receptor mutants from human lung cancers exhibit enhanced catalytic activity and increased sensitivity to gefitinib. Cancer Res 67: 2325-2330.
32. Haura EB, Zheng Z, Song L, Cantor A, Bepler G, (2005) Activated epidermal growth factor receptor-Stat-3 signaling promotes tumor survival in vivo in non-small cell lung cancer. Clin Cancer Res 11: 8288-8294.
33. Yamada S, Shiono S, Joo A, Yoshimura A, (2003) Control mechanism of JAK/STAT signal transduction pathway. FEBS Lett 534: 190-196.
34. Kholodenko BN, Demin OV, Moehren G, Hoek JB, (1999) Quantification of short term signaling by the epidermal growth factor receptor. J Biol Chem 274: 30169-30181.
35. Huang CY, Ferrell JE Jr, (1996) Ultrasensitivity in the mitogen-activated protein kinase cascade. Proc Natl Acad Sci U S A 93: 10078-10083.
36. Ung CY, Li H, Ma XH, Jia J, Li BW, et al. (2008) Simulation of the regulation of EGFR endocytosis and EGFR-ERK signaling by endophilin-mediated RhoA-EGFR crosstalk. FEBS Lett 582: 2283-2290.
37. Schoeberl B, Eichler-Jonsson C, Gilles ED, Muller G, (2002) Computational modeling of the dynamics of the MAP kinase cascade activated by surface and internalized EGF receptors. Nat Biotechnol 20: 370-375.
38. Sasagawa S, Ozaki Y, Fujita K, Kuroda S, (2005) Prediction and validation of the distinct dynamics of transient and sustained ERK activation. Nat Cell Biol 7: 365-373.
39. Kiyatkin A, Aksamitiene E, Markevich NI, Borisov NM, Hoek JB, et al. (2006) Scaffolding protein Grb2-associated binder 1 sustains epidermal growth factor-induced mitogenic and survival signaling by multiple positive feedback loops. J Biol Chem 281: 19925-19938.
40. Hsieh MY, Yang S, Raymond-Stinz MA, Edwards JS, Wilson BS, (2010) Spatio-temporal modeling of signaling protein recruitment to EGFR. BMC Syst Biol 4: 57.
41. Yamada S, Taketomi T, Yoshimura A, (2004) Model analysis of difference between EGF pathway and FGF pathway. Biochem Biophys Res Commun 314: 1113-1120.
42. Walton GM, Chen WS, Rosenfeld MG, Gill GN, (1990) Analysis of deletions of the carboxyl terminus of the epidermal growth factor receptor reveals self-phosphorylation at tyrosine 992 and enhanced in vivo tyrosine phosphorylation of cell substrates. J Biol Chem 265: 1750-1754.
43. Buerger C, Nagel-Wolfrum K, Kunz C, Wittig I, Butz K, et al. (2003) Sequence-specific peptide aptamers, interacting with the intracellular domain of the epidermal growth factor receptor, interfere with Stat3 activation and inhibit the growth of tumor cells. J Biol Chem 278: 37610-37621.
44. Cetin Z, Ozbilim G, Erdogan A, Luleci G, Karauzum SB, (2010) Evaluation of PTEN and Mcl-1 expressions in NSCLC expressing wild-type or mutated EGFR. Med Oncol 27: 853-860.
45. Kloth MT, Laughlin KK, Biscardi JS, Boerner JL, Parsons SJ, et al. (2003) STAT5b, a Mediator of Synergism between c-Src and the Epidermal Growth Factor Receptor. J Biol Chem 278: 1671-1679.
46. Li X, Huang Y, Jiang J, Frank SJ, (2011) Synergy in ERK activation by cytokine receptors and tyrosine kinase growth factor receptors. Cell Signal 23: 417-424.
47. McCubrey JA, Steelman LS, Abrams SL, Bertrand FE, Ludwig DE, et al. (2008) Targeting survival cascades induced by activation of Ras/Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways for effective leukemia therapy. Leukemia 22: 708-722.
48. Martelli AM, Evangelisti C, Chiarini F, Grimaldi C, Cappellini A, et al. (2010) The emerging role of the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin signaling network in normal myelopoiesis and leukemogenesis. Biochim Biophys Acta 1803: 991-1002.
49. Zhang JS, Koenig A, Young C, Billadeau DD, (2011) GRB2 couples RhoU to epidermal growth factor receptor signaling and cell migration. Mol Biol Cell 22: 2119-2130.
50. Saito Y, Furukawa T, Arano Y, Fujibayashi Y, Saga T, (2010) Fusion protein based on Grb2-SH2 domain for cancer therapy. Biochem Biophys Res Commun 399: 262-267.
51. Marshall M, (1995) Interactions between Ras and Raf: key regulatory proteins in cellular transformation. Mol Reprod Dev 42: 493-499.
52. Marais R, Light Y, Paterson HF, Marshall CJ, (1995) Ras recruits Raf-1 to the plasma membrane for activation by tyrosine phosphorylation. EMBO J 14: 3136-3145.
53. Lefloch R, Pouyssegur J, Lenormand P, (2009) Total ERK1/2 activity regulates cell proliferation. Cell Cycle 8: 705-711.
54. Zhang Y, Zheng L, Zhang J, Dai B, Wang N, et al. (2011) Antitumor Activity of Taspine by Modulating the EGFR Signaling Pathway of Erk1/2 and Akt In Vitro and In Vivo. Planta Med.
55. Martinez-Carpio PA, Trelles MA, (2010) The role of epidermal growth factor receptor in photodynamic therapy: a review of the literature and proposal for future investigation. Lasers Med Sci 25: 767-771.
56. Oda K, Matsuoka Y, Funahashi A, Kitano H (2005) A comprehensive pathway map of epidermal growth factor receptor signaling. Mol Syst Biol 1: 2005 0010.
57. Steelman LS, Chappell WH, Abrams SL, Kempf RC, Long J, et al. (2011) Roles of the Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways in controlling growth and sensitivity to therapy-implications for cancer and aging. Aging (Albany NY) 3: 192-222.
58. Balan V, Leicht DT, Zhu J, Balan K, Kaplun A, et al. (2006) Identification of novel in vivo Raf-1 phosphorylation sites mediating positive feedback Raf-1 regulation by extracellular signal-regulated kinase. Mol Biol Cell 17: 1141-1153.
59. Catalanotti F, Reyes G, Jesenberger V, Galabova-Kovacs G, de Matos Simoes R, et al. (2009) A Mek1-Mek2 heterodimer determines the strength and duration of the Erk signal. Nat Struct Mol Biol 16: 294-303.
60. Zhao L, Vogt PK, (2010) Hot-spot mutations in p110alpha of phosphatidylinositol 3-kinase (pI3K): differential interactions with the regulatory subunit p85 and with RAS. Cell Cycle 9: 596-600.
61. Franke TF, Kaplan DR, Cantley LC, Toker A, (1997) Direct regulation of the Akt proto-oncogene product by phosphatidylinositol-3,4-bisphosphate. Science 275: 665-668.
62. Gupta A, Yang Q, Pandita RK, Hunt CR, Xiang T, et al. (2009) Cell cycle checkpoint defects contribute to genomic instability in PTEN deficient cells independent of DNA DSB repair. Cell Cycle 8: 2198-2210.
63. Mahimainathan L, Choudhury GG, (2004) Inactivation of platelet-derived growth factor receptor by the tumor suppressor PTEN provides a novel mechanism of action of the phosphatase. J Biol Chem 279: 15258-15268.
64. Silva A, Yunes JA, Cardoso BA, Martins LR, Jotta PY, et al. (2008) PTEN posttranslational inactivation and hyperactivation of the PI3K/Akt pathway sustain primary T cell leukemia viability. J Clin Invest 118: 3762-3774.
65. Ruff-Jamison S, Zhong Z, Wen Z, Chen K, Darnell JE Jr, et al. (1994) Epidermal growth factor and lipopolysaccharide activate Stat3 transcription factor in mouse liver. J Biol Chem 269: 21933-21935.
66. Mertens C, Darnell JE Jr, (2007) SnapShot: JAK-STAT signaling. Cell 131: 612.
67. Leeman RJ, Lui VW, Grandis JR, (2006) STAT3 as a therapeutic target in head and neck cancer. Expert Opin Biol Ther 6: 231-241.
68. Rusch V, Baselga J, Cordon-Cardo C, Orazem J, Zaman M, et al. (1993) Differential expression of the epidermal growth factor receptor and its ligands in primary non-small cell lung cancers and adjacent benign lung. Cancer Res 53: 2379-2385.
69. Rusch V, Klimstra D, Linkov I, Dmitrovsky E, (1995) Aberrant expression of p53 or the epidermal growth factor receptor is frequent in early bronchial neoplasia and coexpression precedes squamous cell carcinoma development. Cancer Res 55: 1365-1372.
70. ArrayExpress website. Available: http://www.ebi.ac.uk/arrayexpress/. Accessed: 2012 AUG 3.).
71. Kitano H, (2002) Systems biology: a brief overview. Science 295: 1662-1664.
72. Suresh Babu CV, Joo Song E, Yoo YS, (2006) Modeling and simulation in signal transduction pathways: a systems biology approach. Biochimie 88: 277-283.
73. Kirschner MW, (2005) The meaning of systems biology. Cell 121: 503-504.
74. Orton RJ, Sturm OE, Vyshemirsky V, Calder M, Gilbert DR, et al. (2005) Computational modelling of the receptor-tyrosine-kinase-activated MAPK pathway. Biochem J 392: 249-261.
75. Chaudhury S, Igoshin OA, (2010) Dynamic disorder in quasi-equilibrium enzymatic systems. PLoS One 5: e12364.
76. Chen WW, Niepel M, Sorger PK, (2010) Classic and contemporary approaches to modeling biochemical reactions. Genes Dev 24: 1861-1875.
77. Michaelis L MM, (1913) Die Kinetik der Invertinwirkung. Biochem Z 49: 36.
78. Tsakiridis T, Cutz JC, Singh G, Hirte H, Okawara G, et al. (2008) Association of phosphorylated epidermal growth factor receptor with survival in patients with locally advanced non-small cell lung cancer treated with radiotherapy. J Thorac Oncol 3: 716-722.
79. Mukohara T, Kudoh S, Yamauchi S, Kimura T, Yoshimura N, et al. (2003) Expression of epidermal growth factor receptor (EGFR) and downstream-activated peptides in surgically excised non-small-cell lung cancer (NSCLC). Lung Cancer 41: 123-130.
80. Veale D, Kerr N, Gibson GJ, Kelly PJ, Harris AL, (1993) The relationship of quantitative epidermal growth factor receptor expression in non-small cell lung cancer to long term survival. Br J Cancer 68: 162-165.
81. Gandhi J, Zhang J, Xie Y, Soh J, Shigematsu H, et al. (2009) Alterations in genes of the EGFR signaling pathway and their relationship to EGFR tyrosine kinase inhibitor sensitivity in lung cancer cell lines. PLoS One 4: e4576.
82. Reinmuth N, Brandt B, Kunze WP, Junker K, Thomas M, et al. (2000) Ploidy, expression of erbB1, erbB2, P53 and amplification of erbB1, erbB2 and erbB3 in non-small cell lung cancer. Eur Respir J 16: 991-996.
83. Purvis J, Ilango V, Radhakrishnan R, (2008) Role of network branching in eliciting differential short-term signaling responses in the hypersensitive epidermal growth factor receptor mutants implicated in lung cancer. Biotechnol Prog 24: 540-553.
84. Carey KD, Garton AJ, Romero MS, Kahler J, Thomson S, et al. (2006) Kinetic analysis of epidermal growth factor receptor somatic mutant proteins shows increased sensitivity to the epidermal growth factor receptor tyrosine kinase inhibitor, erlotinib. Cancer Res 66: 8163-8171.
85. Brignola PS, Lackey K, Kadwell SH, Hoffman C, Horne E, et al. (2002) Comparison of the biochemical and kinetic properties of the type 1 receptor tyrosine kinase intracellular domains. Demonstration of differential sensitivity to kinase inhibitors. J Biol Chem 277: 1576-1585.
86. Fan YX, Wong L, Deb TB, Johnson GR, (2004) Ligand regulates epidermal growth factor receptor kinase specificity: activation increases preference for GAB1 and SHC versus autophosphorylation sites. J Biol Chem 279: 38143-38150.
87. Helin K, Beguinot L, (1991) Internalization and down-regulation of the human epidermal growth factor receptor are regulated by the carboxyl-terminal tyrosines. J Biol Chem 266: 8363-8368.
88. Huang HS, Nagane M, Klingbeil CK, Lin H, Nishikawa R, et al. (1997) The enhanced tumorigenic activity of a mutant epidermal growth factor receptor common in human cancers is mediated by threshold levels of constitutive tyrosine phosphorylation and unattenuated signaling. J Biol Chem 272: 2927-2935.
89. Lund KA, Lazar CS, Chen WS, Walsh BJ, Welsh JB, et al. (1990) Phosphorylation of the epidermal growth factor receptor at threonine 654 inhibits ligand-induced internalization and down-regulation. J Biol Chem 265: 20517-20523.
90. Wiley HS, Herbst JJ, Walsh BJ, Lauffenburger DA, Rosenfeld MG, et al. (1991) The role of tyrosine kinase activity in endocytosis, compartmentation, and down-regulation of the epidermal growth factor receptor. J Biol Chem 266: 11083-11094.
91. Gioeli D, Mandell JW, Petroni GR, Frierson HF Jr, Weber MJ, (1999) Activation of mitogen-activated protein kinase associated with prostate cancer progression. Cancer Res 59: 279-284.
92. Gee JM, Robertson JF, Ellis IO, Nicholson RI, (2001) Phosphorylation of ERK1/2 mitogen-activated protein kinase is associated with poor response to anti-hormonal therapy and decreased patient survival in clinical breast cancer. Int J Cancer 95: 247-254.
93. Oka H, Chatani Y, Hoshino R, Ogawa O, Kakehi Y, et al. (1995) Constitutive activation of mitogen-activated protein (MAP) kinases in human renal cell carcinoma. Cancer Res 55: 4182-4187.
94. Ito Y, Sasaki Y, Horimoto M, Wada S, Tanaka Y, et al. (1998) Activation of mitogen-activated protein kinases/extracellular signal-regulated kinases in human hepatocellular carcinoma. Hepatology 27: 951-958.
95. Vicent S, Lopez-Picazo JM, Toledo G, Lozano MD, Torre W, et al. (2004) ERK1/2 is activated in non-small-cell lung cancer and associated with advanced tumours. Br J Cancer 90: 1047-1052.
96. Shigematsu H, Gazdar AF, (2006) Somatic mutations of epidermal growth factor receptor signaling pathway in lung cancers. Int J Cancer 118: 257-262.
97. Cortas T, Eisenberg R, Fu P, Kern J, Patrick L, et al. (2007) Activation state EGFR and STAT-3 as prognostic markers in resected non-small cell lung cancer. Lung Cancer 55: 349-355.
98. Yin ZJ, Jin FG, Liu TG, Fu EQ, Xie YH, et al. (2011) Overexpression of STAT3 potentiates growth, survival, and radioresistance of non-small-cell lung cancer (NSCLC) cells. J Surg Res 171: 675-683.
99. Song L, Turkson J, Karras JG, Jove R, Haura EB, (2003) Activation of Stat3 by receptor tyrosine kinases and cytokines regulates survival in human non-small cell carcinoma cells. Oncogene 22: 4150-4165.
100. Emery IF, Battelli C, Auclair PL, Carrier K, Hayes DM, (2009) Response to gefitinib and erlotinib in Non-small cell lung cancer: a restrospective study. BMC Cancer 9: 333.
101. Ganti AK, (2010) Epidermal growth factor receptor signaling in nonsmall cell lung cancer. Cancer Invest 28: 515-525.
102. Gazdar AF, (2009) Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors. Oncogene 28Suppl 1: S24-31.
103. Li H, Schmid-Bindert G, Wang D, Zhao Y, Yang X, et al. (2011) Blocking the PI3K/AKT and MEK/ERK signaling pathways can overcome Gefitinib-resistance in non-small cell lung cancer cell lines. Adv Med Sci 56: 275-284.
104. Okamoto K, Okamoto I, Okamoto W, Tanaka K, Takezawa K, et al. (2010) Role of survivin in EGFR inhibitor-induced apoptosis in non-small cell lung cancers positive for EGFR mutations. Cancer Res 70: 10402-10410.
105. Tang JM, He QY, Guo RX, Chang XJ, (2006) Phosphorylated Akt overexpression and loss of PTEN expression in non-small cell lung cancer confers poor prognosis. Lung Cancer 51: 181-191.
106. Olaussen KA, Soria JC, Morat L, Martin A, Sabatier L, et al. (2003) Loss of PTEN expression is not uncommon, but lacks prognostic value in stage I NSCLC. Anticancer Res 23: 4885-4890.
107. Marsit CJ, Zheng S, Aldape K, Hinds PW, Nelson HH, et al. (2005) PTEN expression in non-small-cell lung cancer: evaluating its relation to tumor characteristics, allelic loss, and epigenetic alteration. Hum Pathol 36: 768-776.
108. Soria JC, Lee HY, Lee JI, Wang L, Issa JP, et al. (2002) Lack of PTEN expression in non-small cell lung cancer could be related to promoter methylation. Clin Cancer Res 8: 1178-1184.
109. Kokubo Y, Gemma A, Noro R, Seike M, Kataoka K, et al. (2005) Reduction of PTEN protein and loss of epidermal growth factor receptor gene mutation in lung cancer with natural resistance to gefitinib (IRESSA). Br J Cancer 92: 1711-1719.
110. Endoh H, Yatabe Y, Kosaka T, Kuwano H, Mitsudomi T, (2006) PTEN and PIK3CA expression is associated with prolonged survival after gefitinib treatment in EGFR-mutated lung cancer patients. J Thorac Oncol 1: 629-634.
111. Sos ML, Koker M, Weir BA, Heynck S, Rabinovsky R, et al. (2009) PTEN loss contributes to erlotinib resistance in EGFR-mutant lung cancer by activation of Akt and EGFR. Cancer Res 69: 3256-3261.
112. Yamamoto C, Basaki Y, Kawahara A, Nakashima K, Kage M, et al. (2010) Loss of PTEN expression by blocking nuclear translocation of EGR1 in gefitinib-resistant lung cancer cells harboring epidermal growth factor receptor-activating mutations. Cancer Res 70: 8715-8725.
113. Yuan J, Mehta PP, Yin MJ, Sun S, Zou A, et al. (2011) PF-04691502, a potent and selective oral inhibitor of PI3K and mTOR kinases with antitumor activity. Mol Cancer Ther 10: 2189-2199.